IL311534A - Methods of treating ocular inflammatory diseases - Google Patents
Methods of treating ocular inflammatory diseasesInfo
- Publication number
- IL311534A IL311534A IL311534A IL31153424A IL311534A IL 311534 A IL311534 A IL 311534A IL 311534 A IL311534 A IL 311534A IL 31153424 A IL31153424 A IL 31153424A IL 311534 A IL311534 A IL 311534A
- Authority
- IL
- Israel
- Prior art keywords
- administration
- immunosuppressant
- patient
- steroidal anti
- inflammatory agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247174P | 2021-09-22 | 2021-09-22 | |
| US202163251874P | 2021-10-04 | 2021-10-04 | |
| PCT/US2022/076876 WO2023049809A1 (en) | 2021-09-22 | 2022-09-22 | Methods of treating ocular inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311534A true IL311534A (en) | 2024-05-01 |
Family
ID=85571480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311534A IL311534A (en) | 2021-09-22 | 2022-09-22 | Methods of treating ocular inflammatory diseases |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12263160B2 (https=) |
| EP (1) | EP4405048A4 (https=) |
| JP (1) | JP2024534570A (https=) |
| AU (1) | AU2022353032A1 (https=) |
| CA (1) | CA3231766A1 (https=) |
| IL (1) | IL311534A (https=) |
| MX (1) | MX2024003580A (https=) |
| WO (1) | WO2023049809A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12102622B2 (en) * | 2021-02-10 | 2024-10-01 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
| US12564616B2 (en) * | 2022-05-20 | 2026-03-03 | Sol Gersh | Composition for respiratory diseases |
| CN116919958A (zh) * | 2023-07-05 | 2023-10-24 | 南方医科大学口腔医院 | 罗氟司特在骨缺损修复治疗中的应用 |
| WO2025024684A1 (en) * | 2023-07-25 | 2025-01-30 | Iolyx Therapeutics, Inc. | Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59410119D1 (de) | 1993-07-02 | 2002-06-20 | Byk Gulden Lomberg Chem Fab | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
| SK122199A3 (en) * | 1997-03-18 | 2000-12-11 | Basf Ag | Methods and compositions for modulating responsiveness to corticosteroids |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| US20040242597A1 (en) * | 2001-09-19 | 2004-12-02 | Thomas Klein | Combination |
| PT1511516E (pt) | 2002-05-28 | 2009-02-20 | Nycomed Gmbh | Preparação farmacêutica para aplicação tópica |
| US20060263350A1 (en) | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
| AU2005267706B2 (en) | 2004-08-02 | 2011-12-08 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
| US7576069B2 (en) | 2004-08-02 | 2009-08-18 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| DE102004046235A1 (de) | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| US8663694B2 (en) | 2005-03-16 | 2014-03-04 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
| DK1906916T3 (da) | 2005-05-10 | 2009-01-19 | Alcon Inc | Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser |
| BRPI0609227A2 (pt) | 2005-05-10 | 2010-03-09 | Alcon Inc | composições de suspensão de nepafenac e outros fármacos oftálmicos, bem como uso das referidas composições no tratamento tópico de distúrbios oftálmicos |
| EP1889620A4 (en) * | 2005-06-09 | 2008-12-10 | Santen Pharmaceutical Co Ltd | EYE DROPS CONTAINING ROFLUMILAST |
| US20090092574A1 (en) | 2006-12-29 | 2009-04-09 | Scott Richard W | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof |
| CA2712017C (en) | 2008-01-18 | 2016-08-09 | Oxagen Limited | Compounds having crth2 antagonist activity |
| RS54413B1 (sr) | 2008-08-22 | 2016-04-28 | Sanofi | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita |
| EP2506878A2 (en) | 2009-12-03 | 2012-10-10 | Lupin Limited | Process for preparing pharmaceutical ophthalmic compositions |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| CN103547580B (zh) | 2011-03-22 | 2016-12-07 | 阿迪维纳斯疗法有限公司 | 取代的稠合三环化合物、其组合物及医药用途 |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| WO2014130922A1 (en) | 2013-02-25 | 2014-08-28 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
| WO2015132708A1 (en) | 2014-03-07 | 2015-09-11 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of roflumilast |
| WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| TW201729810A (zh) | 2015-10-26 | 2017-09-01 | 札爾科製藥公司 | 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法 |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| MX2021003633A (es) | 2018-10-16 | 2021-05-27 | Res Triangle Inst | Dispositivo de depósito biodegradable subcutáneo. |
| EP4061332A4 (en) | 2019-11-24 | 2023-11-29 | Sol-Gel Technologies Ltd. | TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR |
| CN116867480A (zh) * | 2021-02-10 | 2023-10-10 | 洛利克斯治疗有限公司 | 眼部递送罗氟司特的方法 |
| US12102622B2 (en) * | 2021-02-10 | 2024-10-01 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
-
2022
- 2022-09-22 WO PCT/US2022/076876 patent/WO2023049809A1/en not_active Ceased
- 2022-09-22 EP EP22873866.2A patent/EP4405048A4/en active Pending
- 2022-09-22 MX MX2024003580A patent/MX2024003580A/es unknown
- 2022-09-22 AU AU2022353032A patent/AU2022353032A1/en active Pending
- 2022-09-22 US US17/950,802 patent/US12263160B2/en active Active
- 2022-09-22 IL IL311534A patent/IL311534A/en unknown
- 2022-09-22 JP JP2024518365A patent/JP2024534570A/ja active Pending
- 2022-09-22 CA CA3231766A patent/CA3231766A1/en active Pending
-
2025
- 2025-03-06 US US19/072,354 patent/US20250195489A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024003580A (es) | 2024-04-05 |
| AU2022353032A1 (en) | 2024-03-28 |
| EP4405048A4 (en) | 2025-08-06 |
| CA3231766A1 (en) | 2023-03-30 |
| US20230090417A1 (en) | 2023-03-23 |
| US20250195489A1 (en) | 2025-06-19 |
| JP2024534570A (ja) | 2024-09-20 |
| US12263160B2 (en) | 2025-04-01 |
| WO2023049809A1 (en) | 2023-03-30 |
| EP4405048A1 (en) | 2024-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL311534A (en) | Methods of treating ocular inflammatory diseases | |
| JP7169693B2 (ja) | 呼吸器疾患の治療 | |
| KR102312186B1 (ko) | 안 질환 및 장애 치료용 화합물 | |
| PH12021551792A1 (en) | Bi-ligand drug conjugate and use thereof | |
| KR19980701959A (ko) | 신규 제약 조합물 | |
| Andrés-Guerrero et al. | Targeting Schlemm’s canal in the medical therapy of glaucoma: current and future considerations | |
| HK1223842A1 (zh) | 用伊维菌素治疗红斑痤疮的炎性病灶 | |
| KR20140087030A (ko) | 레바미피드와 누액 유지 작용을 갖는 약제를 포함하는 전안부 질환 치료제 | |
| JP7109092B2 (ja) | リドカインおよびジクロフェナクを含む神経障害性疼痛の治療用の医薬用貼付剤 | |
| JP2015522077A5 (https=) | ||
| US20160051526A1 (en) | The Local Treatment of Inflammatory Ophthalmic Disorders | |
| US9187468B2 (en) | Topical ocular analgesic agents | |
| EP4121062A1 (en) | Josamycin for use in prevention and treatment of fibrosis | |
| CN1649575A (zh) | 用氨芬酸或奈帕芬胺治疗血管内皮生长因子介导的血管疾病的方法 | |
| AU2007214300B2 (en) | Method for Ameliorating Pruritus | |
| Alghamdi et al. | Corticosteroid Resistant Pulmonary Fibrosis: Pathophysiology and Management | |
| WO2016085981A1 (en) | Method of inhibiting or treating fibrosis | |
| US11826341B2 (en) | Baicalein analogs for use in neuroprotection and regulation of immune reactivity | |
| JP2006503049A5 (https=) | ||
| Engström | Netarsudil dihydrochloride | |
| Castro Engstroem | Netarsudil dihydrochloride. Rho kinase inhibitor, Norepinephrine transporter (NET) inhibitor, Treatment of glaucoma and ocular hypertension | |
| KR20260005253A (ko) | 코르티코스테로이드 나노현탁액 및 이의 용도 | |
| JP2024517025A (ja) | 乾癬の治療のための方法 | |
| KR20250135809A (ko) | 요독증성 소양증의 치료 | |
| EP4387729A1 (en) | Method for treating parkinson's disease |